Stock listing

LS Exchange:A3C7NH Bioceltix SA Aktie

German listing (LS Exchange) of Bioceltix SA · home listing GPW:BCX

Follow Bioceltix SA into a list and get an email when it puts out news.

Home listing price · GPW:BCX

63.40 PLN -2.00 (-3.1%)

Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, GPW:BCX

Past year -30.9% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
63.30 – 66.00 PLNNov 20, 2026
Volume
4,984 sharesNov 20, 2026
Market cap
350.7M PLNAt the close on Nov 20, 2026 · price × 5.53M shares outstanding
52-week range
57.50 – 99.00 PLNLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
450,544 PLNMedian day 3,413 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Bioceltix SA logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
GPW:BCX · Home63.40 PLN-2.00 (-3.1%)4,98466.0066.0063.3065.40Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · GPW:BCX · PLN, adjusted for splits

DayCloseChange%OpenHighLowVolume
63.40-2.00-3.1%66.0066.0063.304,984
65.40-1.60-2.4%67.0067.0065.103,201
67.00-1.80-2.6%68.7069.0066.303,242
68.80-1.30-1.9%70.7070.7066.803,479
70.10+4.40+6.7%66.0072.0065.6010,089
65.70-2.60-3.8%68.3068.3065.007,941
68.30-0.40-0.6%68.2068.5067.701,107
68.70-0.30-0.4%69.5069.5067.801,346
69.00+1.00+1.5%68.6070.2067.405,822
68.00-2.70-3.8%69.8070.6067.702,875
70.70+2.40+3.5%69.0070.7068.202,098
68.30-0.70-1.0%69.0069.2067.804,006
69.00-1.00-1.4%69.5071.2068.503,642
70.00+0.30+0.4%69.8070.1067.807,305
69.70-2.30-3.2%72.0072.0069.3012,167
72.00-0.90-1.2%73.0075.3071.1020,273
72.90+5.10+7.5%68.9073.0066.6033,965
67.80+4.90+7.8%64.7069.0063.2012,686
62.90+0.40+0.6%63.5064.0062.504,163
62.50-2.30-3.5%64.8065.0061.607,006
64.80+5.30+8.9%59.5064.9059.0011,139
59.50-2.80-4.5%62.7062.7057.5046,257
62.30-2.40-3.7%64.6064.7060.8018,608
64.70-2.60-3.9%67.0067.0062.6018,577
67.30-1.90-2.7%68.7069.6062.5029,329
69.20-0.40-0.6%69.0069.8068.903,413
69.60-0.80-1.1%70.1070.7068.805,351
70.40-2.50-3.4%71.8071.9070.0015,549
72.90+1.60+2.2%71.0072.9071.002,533
71.30-0.80-1.1%72.2074.4071.302,300
72.10+1.30+1.8%71.0075.9071.005,330
70.80-1.00-1.4%71.9071.9070.7010,541
71.80-1.70-2.3%73.4073.4071.209,588
73.50-2.10-2.8%75.1075.9073.405,763
75.60-0.30-0.4%75.9076.0075.101,236
75.90-0.10-0.1%76.0076.0075.00982
76.00+1.10+1.5%75.8076.0074.401,905
74.90+0.50+0.7%74.9075.1074.501,468
74.40-0.40-0.5%74.8075.4074.402,575
74.80-1.20-1.6%75.9075.9074.802,520
76.00+0.50+0.7%76.0076.0074.701,144
75.50+0.20+0.3%75.2075.6074.603,675
75.30+0.30+0.4%75.0076.0074.204,557
75.00-1.00-1.3%76.1076.1075.005,774
76.00+0.60+0.8%75.7076.1075.301,878
75.40-0.20-0.3%75.8075.9075.301,762
75.60-0.40-0.5%76.8076.8075.601,056
76.00-0.40-0.5%76.8077.3076.001,593
76.40-0.60-0.8%77.0077.3076.402,370
77.00-0.30-0.4%77.1077.4076.603,389
77.30-0.10-0.1%77.8077.8076.801,908
77.40-0.10-0.1%77.5077.9076.801,605
77.500.000.0%77.5078.2077.003,630
77.50-1.70-2.1%78.5078.5074.5012,090
79.20-0.20-0.3%79.0079.5078.704,100
79.40+0.20+0.3%78.9079.6078.502,914
79.20-0.10-0.1%79.3079.3078.602,926
79.30-0.70-0.9%80.0080.0079.002,791
80.000.000.0%79.5080.1079.001,636
80.00-0.90-1.1%80.9080.9079.501,325
80.90+0.40+0.5%80.5081.2079.603,176
80.50+0.80+1.0%80.1080.7079.601,813
79.70-0.30-0.4%80.9080.9079.102,608
80.00-0.90-1.1%80.1080.9079.103,811
80.90-0.30-0.4%80.6081.2080.002,025
Ticker
LS Exchange:A3C7NH
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
LS Exchange
Currency
EUR

What changed lately

Latest news

All Bioceltix SA news

Bioceltix SA on 6ix

Sector
Health care
Industry
Biotechnology
News releases
7 in the last 12 months · 11 in all · newest Jun 10, 2026 · oldest 2025
Decks
4 decks · latest Mar 31, 2026

Where Bioceltix SA is listed

ListingExchangeCountryCurrency
GPW:BCX · Home listingGPWPolandPLN
LS Exchange:A3C7NH · This pageLS ExchangeGermanyEUR
Frankfurt:XI3FrankfurtGermanyEUR
Lang & Schwarz:A3C7NHLang & SchwarzGermanyEUR

Valuation

Price/book 5.6× against a median of 1.7×: 9th lowest of 10 Biotechnology companies shown. Statements: 4 quarters to Jun 30, 2026 · price Nov 20, 2026

Enterprise value
294.1M PLN
P/E
Loss
EV/sales
No revenue
EV/EBITDA
Negative EBITDA
Price/book
5.6×
Gross margin
No revenue
Operating margin
No revenue
Net margin
No revenue
Debt to equity
0.0×
Beta
No index for this market yet

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Bioceltix SA · GPW:BCXUS$86.38MUS$72.43Mn/an/an/a5.6×n/a0.0×n/a
Cumberland Pharmaceuticals Inc. · NASDAQ:CPIXUS$87.57MUS$11.59M1.3×0.5×n/a1.2×273.7%0.1×0.72
Retension Pharmaceuticals, Inc. · NASDAQ:RTSNUS$87.57MUS$78.38Mn/an/an/an/an/an/an/a
Equillium, Inc. · NASDAQ:EQUS$87.26MUS$34.71Mn/an/an/a1.7×n/a0.0×1.31
Upstream Bio, Inc. · NASDAQ:UPBUS$87.15M−US$119.4Mn/a−41.6×n/a0.4×n/a0.0×1.95
Senhwa Biosciences Inc · TPEX:6492US$86.77MUS$67.44Mn/a2,117×n/a4.6×n/a0.0×n/a
Perspective Therapeutics, Inc. · AMEX:CATXUS$86.05M−US$114.1Mn/a−570×n/a0.3×n/a0.0×1.47
Pharmosa Biopharm Inc. · TPEX:6875US$86.04MUS$62.27Mn/a38.5×n/a2.1×−658.1%0.1×n/a
Formosa Pharmaceuticals, Inc. · TWSE:6838US$85.43MUS$48.52Mn/a30.4×n/a2.0×−361.4%0.0×n/a
Genome & Co. · KRX:314130US$85.27MUS$37.21Mn/a2.0×n/a1.6×−169.1%0.0×n/a
Anixa Biosciences, Inc. · NASDAQ:ANIXUS$84.82MUS$70.96Mn/an/an/a5.9×n/a0.0×1.45
Median of the othersUS$86.41MUS$42.86M1.3×2.0×1.7×−265.3%0.0×1.45

Forecasts

Analysts' consensus from EODHD, read Nov 21, 2026. Not 6ix's view and not investment advice.

Price target
119.00 PLN · Analysts' mean
EPS, year to Dec 2026
-3.30 · 1 analyst

Team and board

OfficerRole
Łukasz BzdzionCEO / President of the Management Board
Andrij WłachChief Financial Officer, Authorized Signatory (Commercial Proxy)
Grzegorz OstropolskiChief Operating Officer, Authorized Signatory (Commercial Proxy)
Lahoud ToumaChief Technology Officer

Events

QuarterResultsShare move
Q1 2025Apr 28, 2025 · After close+4.1%
Q3 2024Nov 25, 2024 · After close+2.8%

Open Events

Decks

DeckKindSlidesDate
Conference Presentation (March 2026)Conference18 slidesMar 31, 2026
Investor Presentation (December 2025)Investor deck8 slidesDec 10, 2025
Investor Presentation (November 2025)Investor deck8 slidesNov 30, 2025
IPO Roadshow (March 2021)IPO roadshow32 slidesMarch 2021

Open Decks

Financings

RaiseDate
Strategic investment of o series shares
Announced: PLN 87 a share
Buyers: Kvarko Group (New O series shares to be offered in a private subscription as part of an investment deal)
Oct 20, 2025

Open Financings · Read by 6ix AI from the company's releases

Financials

Annual, in PLN

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Revenue0000010.8K1.50K9.20K
Cost of revenue680.1K574.4K1.04M445.4K377.0K3.88M3.48M1.82M
Gross profit-680.1K-574.4K-1.04M-445.4K-377.0K-3.87M-3.48M-1.81M
Research and development3.50M6.36M3.84M1.28M1.93M
Selling, general and administrative9.43M5.21M2.94M1.95M2.06M
Operating income-17.3M-18.8M-15.8M-9.67M-6.21M-3.99M-3.78M-1.92M
Depreciation and amortization680.1K574.4K434.8K445.4K377.0K222.9K48.4K14.0K
EBITDA-16.6M-18.3M-15.4M-9.23M-5.84M-3.77M-3.73M-1.91M
Interest expense208.9K254.2K33.6K31.5K22.9K17.0K20.9K7.25K
Income before tax-15.2M-14.9M-13.7M-8.97M-4.36M-2.37M-1.60M-775.7K
Income tax-15.4K30.5K-5.27K-46.1K41.5K-17.0K-5
Net income-15.2M-14.9M-13.7M-8.92M-4.40M-2.35M-1.60M-775.7K
Earnings per share, basic-3.03-3.28-3.49-2.67-1.39-0.95-0.49-0.24

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Cash and equivalents68.4M33.6M9.31M4.12M6.05M3.20M1.10M1.57M
Receivables2.73M4.97M167.5K27.6K444.3K191.0K635.5K230.0K
Inventory014.0K8.62K0011.8K5.48K1
Current assets71.3M39.4M11.2M4.36M6.51M3.42M1.75M1.81M
Goodwill00000
Total assets75.6M41.9M12.7M5.99M8.20M4.80M3.23M3.30M
Accounts payable640.6K1.49M1.21M959.1K287.8K345.1K57.0K140.2K
Current liabilities2.19M3.20M2.14M2.25M1.91M1.33M1.32M1.73M
Long-term debt00
Total debt314.9K823.9K175.1K293.9K530.8K104.2K165.0K
Total liabilities2.36M3.44M2.27M2.50M2.20M1.48M1.32M1.73M
Shareholders' equity73.3M38.4M10.5M5.15M6.00M3.32M1.91M1.57M
Shares outstanding5.00M4.54M3.92M3.34M3.16M2.47M3.29M3.29M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Cash from operations-12.1M-17.7M-14.7M-7.91M-4.04M-1.51M-1.67M-1.79M
Capital spending-1.97M-242.8K-458.4K-351.7K-5.98K-13.9K-179.7K-523.2K
Free cash flow-14.1M-18.0M-15.2M-8.26M-4.05M-1.53M-1.85M-2.31M
Cash from investing-1.97M-84.2K-458.4K-351.7K134.1K-13.9K-179.7K-523.2K
Cash from financing48.8M42.1M20.4M6.32M6.76M3.63M1.38M1.50M
Share buybacks00000
Change in cash34.8M24.3M5.19M-1.93M2.85M2.10M-469.8K-814.1K

Open Financials

Cap table

Built by 6ix from Bioceltix SA’s releases · as of Oct 20, 2025

Common shares
5,532,253
Fully diluted
5,532,253

Fully diluted

LineShares
Common shares5,532,253

Share count over time

CountShares
Nov 22, 20265,532,253

Open Cap table

Shareholders

HolderSharesValueAs of
State Street(R) SPDR(R) S&P(R) Emerging Markets Small Cap ETF2,627US$63,459Jun 30, 2026

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Andrij WłachChief Financial Officer, Authorized Signatory (Commercial Proxy) · Since at least Nov 5, 2026
Grzegorz OstropolskiChief Operating Officer, Authorized Signatory (Commercial Proxy) · Since at least Nov 5, 2026
Lahoud ToumaChief Technology Officer · Since at least Nov 5, 2026
Łukasz BzdzionCEO / President of the Management Board · Since at least Nov 5, 2026

Open People

Log in to ask 6ix AI your own questions about Bioceltix SA.